ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0007079

alcohol dependence

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. alcohol dependence. Diseases, record MONDO_0007079. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007079

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
alcohol dependence
Open Targets
Open Targets ID
MONDO_0007079
Open Targets
Other names
ALCOHOLIC INTOX CHRONIC, Abuse, Alcohol, Alcohol Abuse, Alcoholic Intoxication, Chronic, Chronic Alcoholic Intoxication, Intoxication, Chronic Alcoholic, alcoholism
Open Targets
Disease Ontology
DOID:0050741
Disease Ontology
NCI Thesaurus
C93040
NCI Thesaurus
Highest stage of its drugs
Approval, for 16 of its 125 drugs, from ATC, DailyMed, PMDA and TTD
Open Targets

Drugs125

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
NALTREXONECHEMBL19019Small moleculeApprovalATC, DailyMed and TTD827777Drugs and targets
TOPIRAMATECHEMBL220492Small moleculeApprovalTTD222121Drugs and targets
ACAMPROSATECHEMBL1201293Small moleculeApprovalATC and TTD151313Drugs and targets
NALMEFENECHEMBL982Small moleculeApprovalATC131111Drugs and targets
DISULFIRAMCHEMBL964Small moleculeApprovalATC and TTD855Drugs and targets
ONDELOPRANCHEMBL2103878Small moleculeApprovalATC422Drugs and targets
NALMEFENE HYDROCHLORIDE DIHYDRATECHEMBL5315055Small moleculeApprovalPMDA211Drugs and targets
ACAMPROSATE CALCIUMCHEMBL2068724Small moleculeApprovalDailyMed and PMDA200Drugs and targets
CALCIUM CARBIMIDECHEMBL3301667Small moleculeApprovalATC and TTD200Drugs and targets
CHLORAL HYDRATECHEMBL455917Small moleculeApprovalTTD100Drugs and targets

1 to 10 of 125

See all 125 drugs

Targets140

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
SLC6A2Monoamine transporter9Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Sodium-dependent noradrenaline transporter releasing agentApprovalhttps://conductscience.org/library/genes/6530Drugs and targets
HTR2A5-hydroxytryptamine receptor 2A7Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonistPhase 3https://conductscience.org/library/genes/3356Drugs and targets
SLC6A4Monoamine transporter7Monoamine transporter inhibitor; Serotonin transporter inhibitor; Sodium-dependent serotonin transporter releasing agentPhase 3https://conductscience.org/library/genes/6532Drugs and targets
DRD2D(2) dopamine receptor6D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonistApprovalhttps://conductscience.org/library/genes/1813Drugs and targets
GABRA1GABA-A receptor; anion channel6GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2554Drugs and targets
GABRA2GABA-A receptor; anion channel6GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2555Drugs and targets
GABRA3GABA-A receptor; anion channel6GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2556Drugs and targets
GABRA4GABA-A receptor; anion channel6GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2557Drugs and targets
GABRA5GABA-A receptor; anion channel6GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2558Drugs and targets
GABRA6GABA-A receptor; anion channel6GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulatorApprovalhttps://conductscience.org/library/genes/2559Drugs and targets

1 to 10 of 140

See all 140 targets

Trials317

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00812461Efficacy of Nalmefene in Patients With Alcohol DependencePhase 36782013-07-09Alcohol DependenceNALMEFENEIts record names the diseaseClinicalTrials.gov
NCT02364947
A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)
Phase 36782019-09-30Alcohol DependenceNALMEFENE HYDROCHLORIDEIts record names the diseaseClinicalTrials.gov
NCT00811941Safety and Efficacy of Nalmefene in Patients With Alcohol DependencePhase 36652013-08-07Alcohol DependenceNALMEFENEIts record names the diseaseClinicalTrials.gov
NCT01218958ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent AdultsPhase 36242010-12-07AlcoholismNALTREXONEIts record names the diseaseClinicalTrials.gov
NCT00811720Efficacy of Nalmefene in Patients With Alcohol DependencePhase 35982013-07-09Alcohol DependenceNALMEFENEIts record names the diseaseClinicalTrials.gov
NCT01218997ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)Phase 34362010-12-13AlcoholismNALTREXONEIts record names the diseaseClinicalTrials.gov
NCT02382276A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol DependencePhase 34052020-07-20Alcohol DependenceNALMEFENEIts record names the diseaseClinicalTrials.gov
NCT04167306Varenicline and Bupropion for Alcohol Use DisorderPhase 23882024-06-07Alcohol Use Disorder, Alcoholism, Alcohol DependenceBUPROPION, VARENICLINEIts record names the diseaseClinicalTrials.gov
NCT00804570A Study for the Treatment of Alcohol DependencePhase 23752017-02-03Alcohol DependenceONDELOPRANIts record names the diseaseClinicalTrials.gov
NCT00920829Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for AlcoholismPhase 43582018-06-04Alcohol DependenceNALTREXONEIts record names the diseaseClinicalTrials.gov

1 to 10 of 317

See all 317 trials

Comparisons in its trials189

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Nalmefene 18.06 mg vs Placebo: serious adverse events7 of 34114 of 337678NCT00812461Trial comparisons
Nalmefene 18.06 mg vs Placebo: serious adverse events35 of 5018 of 164665NCT00811941Trial comparisons
Nalmefene 18.06 mg vs Placebo: serious adverse events17 of 30218 of 296598NCT00811720Trial comparisons
Medisorb Naltrexone 380 mg (VIVITROL) vs Oral Naltrexone 50 mg: Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study336 of 37153 of 65436NCT01218997Trial comparisons
Medisorb Naltrexone 380 mg (VIVITROL) vs Oral Naltrexone 50 mg: serious adverse events49 of 3715 of 65436NCT01218997Trial comparisons
LY2196044 vs Placebo: Number of Participants With Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar)≥10 at Any Time From Baseline Through Week 16 Endpoint0 of 1870 of 188375NCT00804570Trial comparisons
LY2196044 vs Placebo: serious adverse events4 of 1875 of 188375NCT00804570Trial comparisons
Sugar Pill vs Gabapentin Enacarbil: deaths from any cause0 of 1681 of 170338NCT02252536Trial comparisons
Sugar Pill vs Gabapentin Enacarbil: serious adverse events6 of 1688 of 170338NCT02252536Trial comparisons
Medisorb Naltrexone 380 mg vs Medisorb Naltrexone 190 mg: Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While in Study143 of 175130 of 157332NCT01218971Trial comparisons

1 to 10 of 189

See all 189 comparisons in its trials

Papers from its trials195

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
39472130RESULT1PubMed
38597214RESULT1PubMed
34033183RESULT1PubMed
34013473RESULT1PubMed
33997645RESULT1PubMed
32446635RESULT1PubMed
32160422RESULT1PubMed
32053696RESULT1PubMed
31535696RESULT1PubMed
30784955RESULT1PubMed

1 to 10 of 195

See all 195 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007079

GET https://conductscience.org/api/diseases/v1/MONDO_0007079/drugs?page=2

API referenceFor AI assistants